Clinical Characteristics of Prostatic Cancer Detected by Mass Screening

Imai, Kyoichi; Zinbo, Susumu; Shimizu, Kimihiro; Yamanaka, Hidetoshi; Kumasaka, Fuminari; Sato, Zenji

doi:10.1016/s0022-5347(17)41945-8

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MS project began in 1981 in the 22 regions of Gunma Prefecture, Japan. 8 The initial screening proceeded in cooperation with respective towns or city councils, who determined the date and the location. Mass screening information was distributed to males resident in these regions by mail and/or newspapers.…”

Section: Methodsmentioning

confidence: 99%

The correlation of stage and pathology of prostate cancer in Japan

2000

View full text Add to dashboard Cite

Background: Few articles describe stage and pathology distribution of prostate cancer by age, yet understanding these topics may provide clues to the etiology of this disease. The present study describes the distribution of stage and pathology of prostate cancer in terms of age and considers effective detection of early stage cancer by mass screening (MS). Methods: Data presented in this study were based on patient's files from MS and the Gunma Urological Oncology Study Group (GUOSG) registry from 1981 to 1996 in Gunma Prefecture, Japan. Results: Age did not significantly correlate with stage distribution among the GUOSG patients, whereas stage tended to advance with age among the MS patients. Stage B was detected more frequently than any other stage in all age groups of the MS patients, whereas stage C and stage D were detected at similar rates in all age groups. After prostate specific antigen (PSA) had been introduced in MS, the percentage of early stage cancer increased at an earlier age. Pathology distribution did not significantly differ in any group. Conclusions:The data obtained from MS cancer patients showed that tumor stage tends to advance with age. We believe that the younger age group should be examined by MS using PSA to effectively detect early prostate cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

The correlation of stage and pathology of prostate cancer in Japan

2000

View full text Add to dashboard Cite

show abstract

“…). The Japan Cancer Society Ota branch, Gunma Prefecture, carried out the first systematic screening using the serum marker PAP and DRE for men aged ≥60 years in a small restricted area in Gunma, Japan, in 1981 . In the first year of screening, the detection rate of prostate cancer was unexpectedly high, at 1% (7/742).…”

Section: History Of Screening For Prostate Cancer Representative Promentioning

confidence: 99%

Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening

et al. 2019

View full text Add to dashboard Cite

Differences in the incidence and mortality rate of prostate cancer between the USA and Japan have been decreasing over time, and were only twofold in 2017. Therefore, countermeasures against prostate cancer could be very important not only in Western countries, but also in developed Asian countries. Screening for prostate cancer in the general population using transrectal ultrasonography, digital rectal examination and/or prostate acid phosphatase began in Japan in the early 1980s, and screening with prostate‐specific antigen and digital rectal examination has been widespread in the USA since the late 1980s. Large‐ and mid‐scale randomized controlled trials on screening for prostate cancer began around 1990 in the USA, Canada and Europe. However, most of these studies failed as randomized controlled trials because of high contamination in the control arm, low compliance in the screening arm or insufficient screening setting about screening frequency and/or biopsy indication. The best available level 1 evidence is data from the European Randomized Study of Screening for Prostate Cancer and the Göteborg screening study. However, several non‐urological organizations and lay media around the world have mischaracterized the efficacy of prostate‐specific antigen screening. To avoid long‐term confusion about screening for prostate cancer, leading professional urological organizations, including the Japanese Urological Association, are moving toward the establishment of an optimal screening system that minimizes the drawbacks of overdetection, overtreatment and loss of quality of life due to treatment, and maximizes reductions in the risk of death as a result of prostate cancer and the development of metastatic prostate cancer.

show abstract

Clinical Characteristics of Prostatic Cancer Detected by Mass Screening

Cited by 2 publications

References 0 publications

The correlation of stage and pathology of prostate cancer in Japan

The correlation of stage and pathology of prostate cancer in Japan

Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening

Contact Info

Product

Resources

About